The FDA has approved a new drug for some adult patients with endometrial cancer. Jemperli (dostarlimably) — made by U.K. company GSK — is intended for primary advanced or recurrent disease.
The U.S. Food and Drug Administration has approved a new drug for certain adult patients with endometrial cancer. Jemperli — made by British pharmaceutical company GSK — is intended for people with primary advanced or recurrent forms of the cancer, according to the FDA’s Aug. 1 announcement. It is an immunotherapy-based drug, which means it leverages the body’s immune system to attack cancer cells.
In clinical trials, Jemperli showed an improved progression-free survival and overall survival for all patients, according to Dr. Brian Slomovitz, director of gynecologic oncology and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Florida. 'This class of drugs has been used in the second-line setting,' Slomovitz said — meaning they were only used if a first-line treatment was not effective or had intolerable side effects.
In that same month, AstraZeneca’s Imfinzi was approved for patients with advanced or recurrent disease who have a certain biomarker. The AstraZeneca trial also showed improved progression-free survival for all patients. All trials for the new cancer drugs were run through the GOG Foundation, which is the largest cooperative group for all gynecologic oncology research, Slomovitz noted.
These studies have transformed outcomes for patients with endometrial cancer and are poised to change the treatment landscape for the better into the future,' she added. Shannon N. Westin, medical director of the Gynecologic Oncology Center at the University of Texas MD Anderson Cancer Center, said she is 'thrilled' to have multiple new options for patients with advanced and recurrent endometrial cancer after years with no new therapies.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Expands Dostarlimab-gxly Approval for Endometrial CancerThe expanded approval is based on improved survival outcomes observed in the RUBY trial population of patients with advanced or recurrent disease.
Read more »
Transvaginal Ultrasound Often Misses Endometrial Cancer in Black WomenTransvaginal ultrasound used to evaluate the need for endometrial cancer biopsy has high error rate in high-risk Black women, suggesting a need for alternative diagnostic strategies.
Read more »
Many Women Don't Know This Warning Sign of Endometrial CancerToo many women don’t know a key warning sign of endometrial cancer, the most common cancer of the female reproductive organs, a new study shows.
Read more »
FDA OKs best-selling e-cigarette Vuse Alto, but only in tobacco flavorThe authorization only applies to several tobacco-flavored versions of reusable product, which takes cartridges filled with liquid nicotine.
Read more »
FDA: Thousands of Bags of Rice Recalled Over Possible Rodent ContaminationOver 27,500 bags of Lundberg Family Farms rice have been pulled from shelves over potential contamination from rodents.
Read more »
FDA Allows Marketing of Vuse Tobacco-Flavored VapesThe U.S. Food and Drug Administration on Thursday authorized the sale of the country's best-selling e-cigarette.
Read more »